Global Temporal Arteritis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Temporal Arteritis Market Size

• The global temporal arteritis market size was valued at USD 1.60 billion in 2025and is expected to reach USD 2.51 billion by 2033, at a CAGR of 5.80% during the forecast period
• The market growth is largely fueled by the increasing prevalence of autoimmune and inflammatory vascular disorders, growing aging population, and rising awareness regarding early diagnosis of giant cell arteritis (Temporal Arteritis), leading to higher demand for effective therapeutic interventions
• Furthermore, advancements in corticosteroid-sparing therapies, increasing adoption of biologic treatments, and growing focus on precision medicine for inflammatory diseases are establishing Temporal Arteritis treatment solutions as essential components of modern rheumatology care. These converging factors are accelerating the uptake of Temporal Arteritis solutions, thereby significantly boosting the industry's growth

Temporal Arteritis Market Analysis

• Temporal Arteritis (Giant Cell Arteritis) treatment solutions, including corticosteroids, immunosuppressive agents, and biologic therapies, are increasingly vital components of modern healthcare systems due to their role in managing chronic vascular inflammation, preventing vision loss, and improving long-term patient outcomes
• The escalating demand for Temporal Arteritis therapies is primarily fueled by the rising geriatric population, increasing prevalence of autoimmune and inflammatory vascular diseases, and growing awareness regarding early diagnosis and timely treatment to prevent severe complications such as blindness and stroke
• North America dominated the temporal arteritis market with the largest revenue share of 41.7% in 2025, characterized by advanced healthcare infrastructure, strong adoption of biologic therapies, and high awareness of autoimmune disease management, with the U.S. experiencing substantial growth in Temporal Arteritis diagnosis and treatment driven by increasing healthcare expenditure and rising access to specialist rheumatology care
• Asia-Pacific is expected to be the fastest growing region in the temporal arteritis market during the forecast period due to rising healthcare investments, improving diagnostic capabilities, increasing awareness of autoimmune disorders, and expanding access to advanced treatment options across emerging economies
• The oral segment held the largest market revenue share of 67.8% in 2025, driven by the widespread use of oral corticosteroids as the primary treatment for long-term management of temporal arteritis

Report Scope and Temporal Arteritis Market Segmentation

Temporal Arteritis Market Trends

“Advancements in Biologic Therapies and Precision Immunomodulatory Treatment Approaches”

• A significant and accelerating trend in the global Temporal Arteritis market is the increasing adoption of biologic therapies and targeted immunomodulatory treatment approaches aimed at improving long-term disease control and reducing corticosteroid dependence
• For instance, interleukin-6 (IL-6) inhibitors and other biologic agents are increasingly being studied and adopted for patients with giant cell arteritis (temporal arteritis), offering improved remission rates and reduced relapse risk compared to traditional steroid-only regimens
• The growing shift toward steroid-sparing treatment strategies is driven by the need to minimize long-term complications associated with prolonged corticosteroid use, such as osteoporosis, diabetes, hypertension, and vision-related complications
• Furthermore, advancements in immunology and vascular inflammation research are improving understanding of disease mechanisms, enabling more targeted and effective therapeutic development
• The increasing use of imaging techniques such as PET-CT, MRI, and vascular ultrasound is enhancing early diagnosis, disease monitoring, and treatment response evaluation in clinical practice
• This trend toward targeted biologics, improved diagnostics, and personalized immunotherapy approaches is reshaping clinical management and driving innovation in the Temporal Arteritis market globally

Temporal Arteritis Market Dynamics

Driver

“Rising Aging Population and Increasing Prevalence of Autoimmune and Vascular Inflammatory Disorders”

• The growing aging population worldwide is a major factor driving the expansion of the Temporal Arteritis market, as the disease primarily affects individuals over 50 years of age
• For instance, increasing life expectancy and demographic shifts in developed and emerging economies are contributing to a higher pool of elderly patients susceptible to inflammatory vascular conditions such as giant cell arteritis
• Improved awareness among healthcare professionals regarding early symptoms such as persistent headache, jaw pain, and visual disturbances is supporting earlier diagnosis and timely treatment initiation
• Furthermore, increasing access to advanced healthcare infrastructure and specialist rheumatology services is enabling better disease detection and management outcomes
• The rising burden of autoimmune disorders globally is also contributing to increased research activity and pharmaceutical investment in immunosuppressive and biologic therapies for vascular inflammation
• In addition, growing healthcare expenditure and improved reimbursement coverage for chronic inflammatory disease treatments are further supporting market growth

Restraint/Challenge

“Diagnostic Complexity and Long-Term Steroid-Related Adverse Effects”

• The diagnostic complexity of Temporal Arteritis remains a significant challenge, as early symptoms are often non-specific and may overlap with other inflammatory or neurological conditions, leading to delayed diagnosis
• For instance, confirmatory diagnosis often requires temporal artery biopsy or advanced imaging techniques, which may not be readily accessible in all healthcare settings
• In addition, prolonged reliance on high-dose corticosteroid therapy, while effective in controlling inflammation, is associated with significant long-term adverse effects including osteoporosis, weight gain, hypertension, diabetes, and increased infection risk
• The need for long-term treatment monitoring and gradual tapering of steroids increases the overall clinical burden on both patients and healthcare systems
• Limited availability of advanced biologic therapies in certain regions due to high costs and reimbursement constraints may also restrict optimal treatment access
• Addressing these challenges through improved diagnostic protocols, wider access to imaging technologies, development of safer steroid-sparing therapies, and enhanced clinical awareness will be essential for sustained growth in the global Temporal Arteritis market

Temporal Arteritis Market Scope

The market is segmented on the basis of treatment, route of administration, end-users, and distribution channel.

• By Treatment

On the basis of treatment, the Temporal Arteritis market is segmented into corticosteroids, immunosuppressive agents, anticoagulants, and others. The corticosteroids segment dominated the largest market revenue share of 61.4% in 2025, driven by its status as the first-line and most effective treatment for rapid control of inflammation in temporal arteritis (giant cell arteritis). Corticosteroids such as prednisone are widely prescribed due to their ability to quickly reduce vascular inflammation, prevent complications like vision loss, and improve patient outcomes. The increasing prevalence of autoimmune vascular disorders, particularly among the aging population, has significantly contributed to segment growth. In addition, early diagnosis and immediate treatment initiation have strengthened corticosteroid adoption across healthcare systems. Physicians continue to rely on these therapies for both acute management and long-term tapering regimens. Pharmaceutical advancements in low-dose and controlled-release formulations are further improving treatment safety and adherence. Rising awareness regarding early symptom recognition such as headaches and visual disturbances is also supporting timely intervention. Furthermore, expanding access to rheumatology care and improved diagnostic capabilities are expected to sustain strong segment dominance during the forecast period.

The immunosuppressive agents segment is anticipated to witness the fastest CAGR of 22.3% from 2026 to 2033, driven by increasing use in steroid-resistant or relapsing cases of temporal arteritis. Drugs such as methotrexate and tocilizumab are increasingly being adopted as steroid-sparing agents to reduce long-term corticosteroid side effects. Growing focus on personalized treatment approaches and combination therapy strategies is significantly supporting segment growth. In addition, rising clinical research on biologic therapies targeting inflammatory pathways is accelerating innovation. Expanding adoption of advanced immunotherapy options in developed healthcare systems is further contributing to market expansion.

• By Route of Administration

On the basis of route of administration, the Temporal Arteritis market is segmented into oral and parenteral. The oral segment held the largest market revenue share of 67.8% in 2025, driven by the widespread use of oral corticosteroids as the primary treatment for long-term management of temporal arteritis. Oral administration is highly preferred due to ease of use, high patient compliance, and suitability for prolonged therapy regimens. Most patients are initially treated with high-dose oral steroids followed by gradual tapering, making this route central to disease management. The increasing prevalence of chronic inflammatory conditions among elderly populations has significantly supported segment growth. In addition, improved outpatient care systems and regular monitoring protocols are facilitating oral therapy adherence. Pharmaceutical companies are focusing on developing safer oral formulations with reduced adverse effects. Rising awareness regarding early diagnosis and long-term disease control is further strengthening market demand. Furthermore, expanding access to prescription medications through retail and online pharmacies is expected to sustain strong segment dominance during the forecast period.

The parenteral segment is expected to witness the fastest CAGR of 20.9% from 2026 to 2033, driven by increasing use of intravenous corticosteroids in severe or vision-threatening cases. Parenteral administration is critical for rapid disease control in acute flare-ups where immediate intervention is required. Growing adoption of hospital-based emergency treatment protocols is significantly supporting segment growth. In addition, advancements in infusion therapies and biologic injectable treatments are improving clinical outcomes. Rising hospital admissions for severe vasculitis cases are further contributing to demand for parenteral therapies.

• By End-Users

On the basis of end-users, the Temporal Arteritis market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment accounted for the largest market revenue share of 58.9% in 2025, driven by the high rate of diagnosis, emergency treatment needs, and initiation of high-dose corticosteroid therapy in hospital settings. Hospitals serve as primary care centers for managing acute and severe cases of temporal arteritis, particularly those with ocular or neurological complications. Increasing prevalence of age-related vascular inflammatory diseases has significantly contributed to hospital-based treatment demand. In addition, hospitals are equipped with advanced diagnostic tools such as temporal artery biopsy and imaging technologies essential for accurate diagnosis. Expanding healthcare infrastructure and rising geriatric population globally are further strengthening market growth. Physicians increasingly rely on hospital settings for initial disease stabilization and treatment planning. Furthermore, supportive reimbursement frameworks and improved access to specialist care are expected to sustain strong segment dominance during the forecast period.

The homecare segment is anticipated to witness the fastest CAGR of 21.7% from 2026 to 2033, driven by the growing preference for long-term oral corticosteroid therapy management at home. Patients with stable conditions increasingly prefer homecare due to convenience, reduced hospitalization costs, and improved quality of life. Rising adoption of telemedicine and remote monitoring systems is significantly supporting safe outpatient management. In addition, increasing availability of home nursing support and chronic disease management programs is further accelerating segment growth.

• By Distribution Channel

On the basis of distribution channel, the Temporal Arteritis market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the largest market revenue share of 50.6% in 2025, driven by the high volume of inpatient prescriptions for corticosteroids and immunosuppressive therapies. Hospital pharmacies play a crucial role in ensuring immediate drug availability during emergency treatment of acute temporal arteritis cases. The increasing number of hospital admissions for vasculitis-related complications has significantly contributed to segment growth. In addition, hospital pharmacies are integrated with clinical monitoring systems to ensure safe and controlled medication dispensing. Expanding healthcare infrastructure and growing investment in specialized vascular care units are further supporting market demand. Rising adoption of standardized treatment protocols in hospitals is also strengthening segment dominance. Furthermore, increasing focus on patient safety and drug management compliance is expected to sustain strong market growth during the forecast period.

The online pharmacy segment is expected to witness the fastest CAGR of 23.4% from 2026 to 2033, driven by the rapid expansion of digital healthcare platforms and increasing demand for convenient medication access. Online pharmacies provide easy home delivery of long-term corticosteroid prescriptions and supportive medications, improving treatment adherence. The growing adoption of teleconsultation services for chronic disease management is significantly accelerating segment growth. In addition, rising internet penetration, smartphone usage, and digital payment systems are supporting broader market expansion. Regulatory improvements enabling safe online prescription fulfillment are further contributing to segment growth.

Temporal Arteritis Market Regional Analysis

• North America dominated the temporal arteritis market with the largest revenue share of 41.7% in 2025, characterized by advanced healthcare infrastructure, strong adoption of biologic therapies, and high awareness of autoimmune disease management
• The region benefits from well-established rheumatology care networks, increasing use of corticosteroids and targeted biologic agents, and growing emphasis on early diagnosis and long-term disease management
• Furthermore, rising healthcare expenditure, strong clinical research in inflammatory and autoimmune disorders, and expanding access to specialist care are significantly contributing to market growth across North America

U.S. Temporal Arteritis Market Insight

The U.S. temporal arteritis market captured the largest revenue share within North America in 2025, driven by increasing healthcare expenditure, rising prevalence of autoimmune disorders, and expanding access to specialist rheumatology care. The country is witnessing substantial growth in diagnosis rates due to improved awareness and advanced diagnostic tools such as imaging and laboratory biomarkers. In addition, strong adoption of biologic therapies, continuous clinical research advancements, and growing emphasis on precision medicine are supporting market expansion in the U.S.

Europe Temporal Arteritis Market Insight

Europe temporal arteritis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing prevalence of autoimmune diseases and strong healthcare systems supporting early diagnosis and treatment. The region benefits from rising adoption of biologic and corticosteroid therapies, along with growing awareness of inflammatory vascular conditions. Moreover, expanding geriatric population, advancements in immunology research, and improving access to specialist care are contributing significantly to market growth across Europe.

U.K. Temporal Arteritis Market Insight

The U.K. temporal arteritis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness of autoimmune and inflammatory disorders and strong access to specialist healthcare services. The country’s structured public healthcare system supports early diagnosis and long-term disease management. Furthermore, growing adoption of biologic therapies and improved clinical guidelines for giant cell arteritis treatment are contributing to market expansion in the U.K.

Germany Temporal Arteritis Market Insight

The Germany temporal arteritis market is expected to expand at a considerable CAGR during the forecast period, fueled by advanced healthcare infrastructure, strong focus on autoimmune disease research, and increasing adoption of innovative biologic treatments. Germany’s emphasis on precision medicine and early diagnostic approaches is supporting improved disease detection and management. In addition, rising elderly population and increasing healthcare investments are positively influencing market growth in the country.

Asia-Pacific Temporal Arteritis Market Insight

Asia-Pacific temporal arteritis market is expected to be the fastest growing region in the Temporal Arteritis market during the forecast period due to rising healthcare investments, improving diagnostic capabilities, increasing awareness of autoimmune disorders, and expanding access to advanced treatment options across emerging economies. The region is witnessing rapid improvements in healthcare infrastructure, increasing availability of specialist care, and growing adoption of modern diagnostic technologies. In addition, rising government initiatives focused on chronic disease management and expanding insurance coverage are further accelerating market growth.

Japan Temporal Arteritis Market Insight

The Japan temporal arteritis market is gaining momentum due to the country’s advanced healthcare system, aging population, and strong focus on chronic disease management. Increasing awareness of autoimmune conditions and growing adoption of advanced diagnostic tools are supporting early detection and treatment. Furthermore, Japan’s emphasis on high-quality specialist care and precision medicine is contributing to the expanding use of biologic and immunosuppressive therapies.

China Temporal Arteritis Market Insight

The China temporal arteritis market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to expanding healthcare infrastructure, increasing awareness of autoimmune disorders, and rising healthcare expenditure. The country is witnessing improving access to advanced diagnostic and treatment options supported by healthcare modernization initiatives. In addition, growing investments in specialty care services, expanding hospital networks, and increasing adoption of biologic therapies are key factors propelling market growth in China.

Temporal Arteritis Market Share

The Temporal Arteritis industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Roche Holding AG (Switzerland)
• Novartis AG (Switzerland)
• GlaxoSmithKline plc (U.K.)
• Sanofi S.A. (France)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Bayer AG (Germany)
• AstraZeneca plc (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Reddy’s Laboratories Ltd. (India)
• Cipla Limited (India)
• Lupin Limited (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Biogen Inc. (U.S.)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Bristol Myers Squibb Company (U.S.)

Latest Developments in Global Temporal Arteritis Market

• In June 2021, the updated American College of Rheumatology (ACR) guidelines for giant cell arteritis (temporal arteritis) were published, reinforcing the use of glucocorticoid-sparing agents such as tocilizumab as a key advancement in disease management. This guideline update standardized modern treatment pathways and encouraged biologic adoption in moderate-to-severe cases
• In March 2024, Celltrion received U.S. FDA approval for Avtozma, a biosimilar to tocilizumab (Actemra), indicated for multiple autoimmune diseases including giant cell arteritis. The approval expanded access to IL-6 inhibitor therapy and improved affordability of biologic treatment options for temporal arteritis patients
• In April 2025, AbbVie announced U.S. FDA approval of RINVOQ® (upadacitinib) for the treatment of adults with giant cell arteritis (temporal arteritis). The drug became the first oral JAK inhibitor approved for GCA, demonstrating superior sustained remission rates and steroid-sparing effects in Phase III SELECT-GCA trials
• In April 2025, clinical trial results from the SELECT-GCA Phase III study showed that upadacitinib achieved significantly higher sustained remission rates (46% vs 29% placebo) while reducing long-term corticosteroid dependence, marking a major breakthrough in targeted oral therapy for temporal arteritis
• In July 2025, Novartis reported that its IL-17 inhibitor Cosentyx (secukinumab) failed to meet primary endpoints in a Phase III trial for giant cell arteritis, highlighting ongoing challenges in biologic development for inflammatory vasculitis despite earlier Phase II promise
• In July 2025, clinical reviews emphasized that JAK inhibitors such as upadacitinib are reshaping the treatment algorithm for temporal arteritis, offering broader cytokine pathway inhibition compared to IL-6 blockers and reducing cumulative glucocorticoid toxicity

SKU-54490